Overcome Prostate Cancer Resistance to Immune Checkpoint Therapy with Ketogenic Diet-Induced Epigenetic Reprogramming
Murphy, S.; Rahmy, S.; Gan, D.; Zhu, Y.; Manyak, M.; Li, J.; Lu, X.; Lu, X.
Show abstract
Advanced prostate cancer (PCa) is overwhelmingly resistant to immune checkpoint blockade (ICB) therapy, representing a formidable clinical challenge. In this study, we developed a syngeneic murine PCa model with acquired ICB resistance. Using this model, synergistic efficacy was achieved by combining anti-PD1 and anti-CTLA4 antibodies with histone deacetylase inhibitor (HDACi) vorinostat, a cyclic ketogenic diet (CKD), or supplementation of ketone body {beta}-hydroxybutyrate (BHB, endogenous HDACi) via 1,3-butanediol-admixed food. CKD and BHB supplementation delayed PCa tumors as monotherapy, and both BHB and adaptive immunity are required for the anti-tumor activity of CKD. Single-cell transcriptomic and proteomic profiling revealed that the HDACi and ketogenesis-enhanced ICB therapy involves cancer-cell-intrinsic (upregulated MHC class I molecules) and extrinsic mechanisms (CD8+ T cell chemoattraction, M1/M2 macrophage rebalancing, monocyte differentiation toward antigen presenting cells, and diminished neutrophils). Overall, these findings underscore the potential of using HDACi and optimized KD to enhance ICB therapy for PCa.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 98%
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 97%
- Single-Cell RNA Sequencing Reveals the Effects of Chemotherapy on Human Pancreatic Adenocarcinoma and its Tumor Microenvironment 96%
Similar papers in this journal
- Pharmacologically targeting KRASG12D in PDAC models:tumor cell intrinsic and extrinsic impact 95%
- CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis 95%
- Nutrient availability dictates cancer metabolism-based therapeutic responses of non-oncology drugs 94%
Similar papers in this journal
- Cancer-cell-derived cGAMP limits the activity of tumor-associated CD8+ T cells 96%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 96%
- Inflammatory cytokines mediate the induction of and awakening from metastatic dormancy 95%
Similar papers in this journal
- Conserved angio-immune subtypes of the cancer microenvironment predict response to immune checkpoint blockade therapy 95%
- Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes 95%
- Hypoxia-Sensing CAR T-Cells Provide Safety and Efficacy in Treating Solid Tumors 94%
Similar papers in this journal
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 96%
- Cancer-associated fibroblast compositions change with breast cancer progression linking S100A4 and PDPN ratios with clinical outcome 95%
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.